Gilead Sciences Earnings: What to Watch

Gilead Sciences Inc. is scheduled to announce its fourth-quarter earnings Feb. 3. Last year, Gilead’s Sovaldi had the top-selling drug launch in history with more than $8.5 billion in sales through the end of September. The fourth-quarter results will give a hint how Gilead’s newest hepatitis C pill, Harvoni, approved Oct. 10, will fare. So far, the signs are positive: insurance claims data from Symphony Health Solutions indicate Harvoni’s launch during its first 14 weeks on sale is at a higher volume than Sovaldi’s.

read more